KR101189693B1 - 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료 - Google Patents

10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료 Download PDF

Info

Publication number
KR101189693B1
KR101189693B1 KR1020117012373A KR20117012373A KR101189693B1 KR 101189693 B1 KR101189693 B1 KR 101189693B1 KR 1020117012373 A KR1020117012373 A KR 1020117012373A KR 20117012373 A KR20117012373 A KR 20117012373A KR 101189693 B1 KR101189693 B1 KR 101189693B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
cell lymphoma
deazaaminopterin
propargyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020117012373A
Other languages
English (en)
Korean (ko)
Other versions
KR20110081327A (ko
Inventor
오웬 에이. 오코너
프란시스 시로트낙
Original Assignee
슬로안-케테링인스티튜트퍼캔서리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101189693(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 슬로안-케테링인스티튜트퍼캔서리서치 filed Critical 슬로안-케테링인스티튜트퍼캔서리서치
Publication of KR20110081327A publication Critical patent/KR20110081327A/ko
Application granted granted Critical
Publication of KR101189693B1 publication Critical patent/KR101189693B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020117012373A 2004-05-30 2005-05-31 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료 Expired - Lifetime KR101189693B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
US60/521,593 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067024620A Division KR101189692B1 (ko) 2004-05-30 2005-05-31 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포림프종의 치료

Publications (2)

Publication Number Publication Date
KR20110081327A KR20110081327A (ko) 2011-07-13
KR101189693B1 true KR101189693B1 (ko) 2012-10-10

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117012373A Expired - Lifetime KR101189693B1 (ko) 2004-05-30 2005-05-31 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료

Country Status (23)

Country Link
US (4) US7939530B2 (https=)
EP (1) EP1750716B1 (https=)
JP (1) JP5005532B2 (https=)
KR (1) KR101189693B1 (https=)
CN (2) CN102824346B (https=)
AT (1) ATE405272T1 (https=)
AU (1) AU2005249516B2 (https=)
BR (1) BRPI0510895A (https=)
CA (1) CA2565968C (https=)
DE (1) DE602005009176D1 (https=)
DK (1) DK1750716T3 (https=)
ES (1) ES2313365T3 (https=)
HR (1) HRP20080569T3 (https=)
ME (1) ME01087B (https=)
MX (1) MXPA06013559A (https=)
NO (1) NO337276B1 (https=)
NZ (2) NZ576849A (https=)
PL (1) PL1750716T3 (https=)
PT (1) PT1750716E (https=)
RS (1) RS50622B (https=)
SI (1) SI1750716T1 (https=)
WO (2) WO2005117891A1 (https=)
ZA (1) ZA200609266B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2565968C (en) 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
EP2575466B1 (en) * 2010-06-02 2015-04-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT944389E (pt) * 1996-07-17 2008-12-03 Sloan Kettering Inst Cancer Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CA2565968C (en) * 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Clin. Oncol., Vol. 21, pages 1556-1561 (2003)*
Leukemia and Lymphoma, Vol 44, pages 1027-1035 (2003)*

Also Published As

Publication number Publication date
HRP20080569T3 (en) 2008-12-31
US8299078B2 (en) 2012-10-30
RS50622B (sr) 2010-06-30
KR20110081327A (ko) 2011-07-13
WO2005117892A1 (en) 2005-12-15
CN102824346B (zh) 2015-04-22
BRPI0510895A (pt) 2007-11-27
CA2565968A1 (en) 2005-12-15
MXPA06013559A (es) 2007-04-24
US7939530B2 (en) 2011-05-10
AU2005249516A1 (en) 2005-12-15
EP1750716A1 (en) 2007-02-14
EP1750716B1 (en) 2008-08-20
CN102824346A (zh) 2012-12-19
WO2005117891A1 (en) 2005-12-15
SI1750716T1 (sl) 2009-06-30
PL1750716T3 (pl) 2009-01-30
US20080058280A1 (en) 2008-03-06
DK1750716T3 (da) 2008-12-08
JP5005532B2 (ja) 2012-08-22
NO337276B1 (no) 2016-02-29
US20100120777A1 (en) 2010-05-13
DE602005009176D1 (de) 2008-10-02
CA2565968C (en) 2013-01-08
AU2005249516B2 (en) 2010-11-18
NZ576849A (en) 2011-03-31
NZ551082A (en) 2009-06-26
ME01087B (me) 2012-12-20
ES2313365T3 (es) 2009-03-01
NO20065971L (no) 2006-12-22
US20050267117A1 (en) 2005-12-01
ZA200609266B (en) 2008-12-31
US20130053391A1 (en) 2013-02-28
CN1960734A (zh) 2007-05-09
ATE405272T1 (de) 2008-09-15
HK1177901A1 (en) 2013-08-30
PT1750716E (pt) 2008-11-04
US7622470B2 (en) 2009-11-24
JP2008501038A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
KR101189693B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료
US10875859B2 (en) Thymoquinone/harmaline and related reaction products
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
US11453664B2 (en) Thymoquinone/harmaline and related reaction products
US11452715B2 (en) Thymoquinone/harmaline and related reaction products
US20090281105A1 (en) Radiotherapy enhancer
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
KR101189692B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포림프종의 치료
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
US4005204A (en) Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
EP2331091A1 (en) Pharmaceutical combination of 1-(2-tetrahydrofuryl)-5-fluorouracil and caffeic acid phenethyl ester for oral treating of tumors
HK1177901B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
Ajani et al. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas
US4005203A (en) Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine
CN121490088A (zh) 甲基莲心碱和pd-1抑制剂联用的应用和联用药物
Mori et al. Feasibility and the efficacy of megadose chemotherapy with peripheral blood stem cell transplantation (PBSCT) for small cell lung cancer (SCLC) wereevaluated. Autologousperipheral blood stemcell (APBSC) was collected after induction chemotherapy (Extensive disease: CDDP+ etoposide+ ADM, Limited disease: CDDP+ etoposide) followed by
AU1859399A (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20151002

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160923

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170926

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180921

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20200924

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20210929

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20220922

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250601

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION